Abstract
Individuals with likely exposure to the highly infectious SARS-CoV-2 do not necessarily develop PCR or antibody positivity, suggesting some may clear sub-clinical infection before seroconversion. T cells can contribute to the rapid clearance of SARS-CoV-2 and other coronavirus infections1–5. We hypothesised that pre-existing memory T cell responses, with cross-protective potential against SARS-CoV-26–12, would expand in vivo to mediate rapid viral control, potentially aborting infection. We studied T cells against the replication transcription complex (RTC) of SARS-CoV-2 since this is transcribed first in the viral life cycle13–15and should be highly conserved. We measured SARS-CoV-2-reactive T cells in a cohort of intensively monitored healthcare workers (HCW) who remained repeatedly negative by PCR, antibody binding, and neutralisation for SARS-CoV-2 (exposed seronegative, ES). 16-weeks post-recruitment, ES had memory T cells that were stronger and more multispecific than an unexposed pre-pandemic cohort, and more frequently directed against the RTC than the structural protein-dominated responses seen post-detectable infection (matched concurrent cohort). The postulate that HCW with the strongest RTC-specific T cells had an abortive infection was supported by a low-level increase in IFI27 transcript, a robust early innate signature of SARS-CoV-2 infection16. We showed that the RNA-polymerase within RTC was the largest region of high sequence conservation across human seasonal coronaviruses (HCoV) and was preferentially targeted by T cells from UK and Singapore pre-pandemic cohorts and from ES. RTC epitope-specific T cells capable of cross-recognising HCoV variants were identified in ES. Longitudinal samples from ES and an additional validation cohort, showed pre-existing RNA-polymerase-specific T cells expanded in vivo following SARS-CoV-2 exposure, becoming enriched in the memory response of those with abortive compared to overt infection. In summary, we provide evidence of abortive seronegative SARS-CoV-2 infection with expansion of cross-reactive RTC-specific T cells, highlighting these highly conserved proteins as targets for future vaccines against endemic and emerging Coronaviridae.
Competing Interest Statement
A.B. is a cofounder of Lion TCR, a biotechnology company that develops T cell receptors for the treatment of virus-related diseases and cancers. RJB and DMA are members of the Global T cell Expert Consortium and have consulted for Oxford Immunotec outside the submitted work. All other authors have no competing interests related to the study.
Clinical Trial
NCT04318314
Clinical Protocols
https://wellcomeopenresearch.org/articles/5-179
Funding Statement
The COVIDsortium is supported by funding donated by individuals, charitable Trusts, and corporations including Goldman Sachs, Citadel and Citadel Securities, The Guy Foundation, GW Pharmaceuticals, Kusuma Trust, and Jagclif Charitable Trust, and enabled by Barts Charity with support from UCLH Charity. Wider support is acknowledged on the COVIDsortium website. Institutional support from Barts Health NHS Trust and Royal Free NHS Foundation Trust facilitated study processes, in partnership with University College London and Queen Mary University London. This study was funded by UKRI/NIHR UK-CIC (supporting LS and MKM). MKM is also supported by Wellcome Trust Investigator Award (214191/Z/18/Z) and CRUK Immunology grant (26603) and LS by a Medical Research Foundation fellowship (044-0001). MN is supported by the Wellcome Trust (207511/Z/17/Z) and by NIHR Biomedical Research Funding to UCL and UCLH. AB is supported by Grant support a Special NUHS COVID-19 Seed Grant Call, Project NUHSRO/2020/052/RO5+5/NUHS-COVID/6 (WBS R-571-000-077-733). JCM, CM and TAT are directly and indirectly supported by the University College London Hospitals (UCLH) and Barts NIHR Biomedical Research Centres and through the British Heart Foundation (BHF) Accelerator Award (AA/18/6/34223). TAT is funded by a BHF Intermediate Research Fellowship (FS/19/35/34374). AMV, AM, CM and JCM were supported by the UKRI/MRC Covid-19 Rapid response grant COV0331 MR/V027883/1. A.M. is supported by Rosetrees Trust, The John Black Charitable Foundation, and Medical College of St Bartholomews Hospital Trust. RJB and DMA are supported by MRC (MR/S019553/1, MR/R02622X/1 and MR/V036939/1), NIHR Imperial Biomedical Research Centre (BRC): ITMAT, Cystic Fibrosis Trust SRC (2019SRC015), and Horizon 2020 Marie Sklodowska-Curie Innovative Training Network (ITN) European Training Network (No 860325). Funding for the HLA imputed data was provided by UKRI/MRC Covid-19 rapid response grant (Cov-0331 - MR/V027883/1). LEM is supported by a Medical Research Council Career Development Award (MR/R008698/1). The funders had no role in study design data collection, data analysis, data interpretation, or writing of the report.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The COVIDsortium bioresource was approved by the ethical committee of UK National Research Ethics Service (20/SC/0149) and registered on ClinicalTrials.gov (NCT04318314). Full study details of the bioresource (participant screening, study design, sample collection, and sample processing) have been previously described (Augusto et al Wellcome Open Res 2020, Reynolds et al Sci imm 2020). The cohort of medical students and laboratory staff was approved by UCL Ethics (Project ID Number: 13545/001) and pre-pandemic healthy donor samples were collected and cryopreserved before August 2019 under ethics numbers 11/LO/0421. All subjects gave written informed consent and the study conformed to the principles of the Helsinki Declaration.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵$ The members of the COVIDsortium investigators and COVIDsortium immune correlates network can be found at the end of the Acknowledgments.
Data Availability
All relevant data analysed during this study are included in this published article (and its supplementary information files). Custom scripts used to perform the homology searches, heatmap visualisation and permutation testing are hosted on GitHub (https://github.com/cednotsed/tcell_cross_reactivity_covid.git). The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request. Correspondence and requests for materials should be addressed to MKM or LS.
https://github.com/cednotsed/tcell_cross_reactivity_covid.git
